key: cord-0961229-numkju2l authors: Yazdani, Amid; Mirmosayyeb, Omid; Ghaffary, Elham Moases; Hashemi, Mozhgan Sadat; Ghajarzadeh, Mahsa title: COVID-19 vaccines and patients with multiple sclerosis: willingness, unwillingness and hesitancy: a systematic review and meta-analysis date: 2022-04-05 journal: Neurol Sci DOI: 10.1007/s10072-022-06051-6 sha: ad3243143c1525fcb87ba7be37b577074f87afc0 doc_id: 961229 cord_uid: numkju2l OBJECTIVE: The purpose of this study was to determine the pooled prevalence of vaccination willingness, unwillingness, and hesitancy among patients with multiple sclerosis. METHODS: Databases including PubMed, Scopus, EMBASE, Web of Science, and Google Scholar were searched. by two expert researchers, as well as references in the included studies, which were published before October 2021. RESULTS: Three hundred eighty articles were found in four data bases. One hundred eighty-two studies remained following deleting duplicates. Finally, ten studies remained for the meta-analysis. Totally, 5983 patients with MS were assessed. The pooled prevalence of willingness to vaccination among patients with MS was 76% (95% CI: 67–85%) (I(2) = 98.4%, p < 0.001). Unwillingness pooled prevalence to vaccination among patients with MS was 2% (95% CI: 2–3%) (I(2) = 97.9%, p < 0.001). Hesitancy pooled prevalence to vaccination among patients with MS was 0% (I(2) = 98%, p < 0.001). CONCLUSION: According to the findings of this systematic review and meta-analysis, more than two-thirds of patients with MS were willing to obtain COVID-19 vaccines. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19 infection and was first introduced in China and is now in the pandemic stage [1] . Patients with underlying disease, especially autoimmune disease, were considered at higher risk of the severe form of the disease [2] . A comprehensive review and meta-analysis assessed the pooled prevalence of COVID-19 infection and hospitalization in patients with MS to be 4% and 10%, respectively [3] . Vaccination against SARS-CoV-2 is the primary longterm strategy to stop this pandemic all over the world [4] . Concerns about vaccination were raised among patients with MS and their health care providers regarding disease exacerbation, side effects, and efficacy [5] . Willingness to get vaccines differs among nations, age groups, and genders [6] . Previous studies reported various rates of willingness regarding SARS-CoV-2 vaccination among patients with MS. So, we designed this systematic review and metaanalysis to estimate the pooled prevalence of vaccination willingness among MS patients. Databases including PubMed, Scopus, EMBASE, Web of Science, and Google Scholar were searched by two expert researchers, as well as references of the included studies published before October 2021. Our search strategy was: ((Sclerosis AND multiple) OR (sclerosis AND disseminated) OR "disseminated sclerosis" OR "multiple sclerosis" OR "acute fulminating" OR MS OR "Multiple sclerosis") AND ("COVID 19 Vaccin*" OR (Vaccin* AND COVID-19) OR "COVID-19 Virus Vaccin*" OR (Vaccin* AND "COVID-19 Virus") OR ("Virus Vaccin*" AND COVID-19) OR "COVID-19 Virus Vaccin*" OR "COVID 19 Virus Vaccin*" OR ("Virus Vaccin*" AND COVID-19) OR "COVID19 Virus Vaccin*" OR (Vaccin* AND "COVID19 Virus") OR ("Virus Vaccin*" AND COVID19) OR "COVID19 Vaccin*" OR (Vaccin* AND COVID19) OR "SARS-CoV-2 Vaccin*" OR "SARS CoV 2 Vaccin*" OR (Vaccin* AND SARS-CoV-2) OR "SARS2 Vaccin*" OR (Vaccin* AND SARS2) OR "Coronavirus Disease 2019 Vaccin*" OR "Coronavirus Disease 2019 Virus Vaccin*" OR "Coronavirus Disease-19 Vaccin*" OR (Vaccin* AND "Coronavirus Disease-19") OR "Coronavirus Disease 19 Vaccin*" OR "COVID 19 Vaccin*" OR (Vaccin* AND "COVID 19") OR "2019-nCoV Vaccin*" OR "2019 nCoV Vaccin*" OR (Vaccin* AND 2019-nCoV) OR "2019 Novel Coronavirus Vaccin*" OR "2019-nCoV Vaccin*" OR "2019 nCoV Vaccin*" OR (Vaccin* AND 2019-nCoV) OR "COVID-19 Vaccin*" OR "SARS Coronavirus 2 Vaccin*") AND (willingness OR accept* OR demand OR (vaccine* AND readiness) OR (vaccine* AND readiness) OR Hesita* OR (vaccine* AND hesita*) OR (vaccine* AND accept*) OR (vaccine* AND uptake*) OR (vaccine* AND adopt*) OR Attitude* OR decision-making OR (decision AND making) OR (health AND behaviour) OR "conspiracy theories" OR "conspiracy belie*" OR "obtain COVID-19 vaccin" OR (vaccine AND intention)). Our inclusion criteria were based on cross-sectional studies that repor ted the patients with MS who answered questions regarding COVID-19 vaccination. All answers were based on questions designed in the surveys. Our exclusion criteria were non-English studies, case reports, case-control, letters to the editor, and crosssectional studies with no clear criteria. We e x t r a c t e d d a t a g i ve n t h e d e m o g r a p h i c data, ar ticle character istics, the number of those willing to have vaccination, and t he number of those who were hesitant or unwilling. The Newcastle-Ottawa quality assessment scale (NOS) that was adapted for cross-sectional studies was investigated for the risk of bias [7] . We did all statistical analyses using STATA (Version 14.0; Stata Corp LP, College Station, TX, USA). We used random effects to estimate pooled prevalence. To determine heterogeneity, inconsistency (I 2 ) was calculated. We found 380 studies in the databases; following eliminating duplicates, 182 studies remained. Finally, ten articles used for conducting meta-analysis ( Fig. 1 ). Ten articles were included. Totally, 5983 MS patients were assessed. The characteristics of the included studies are shown in Table 1 . The pooled prevalence of willingness to vaccination among patients with MS was 76% (95% CI: 67-85%) (I 2 = 98.4%, p < 0.001) (Fig. 2) . The pooled prevalence of unwillingness to vaccination among patients with MS was 2% (95% CI: 2-3%) (I 2 = 97.9%, p < 0.001) (Fig. 3) . The pooled prevalence of hesitancy to vaccination among patients with MS was 0% (I 2 = 98%, p < 0.001) (Fig. 4) . The percentage of willingness, unwillingness, and hesitancy in patients with MS to get COVID-19 vaccines is shown based on countries (Fig. 5 ). This study is the first systematic review and metaanalysis to assess the willingness, unwillingness, and hesitancy rates regarding COVID-19 vaccination among patients with MS. The results show that the pooled willingness rate was 76%, ranging from 49 to 94%. The pooled prevalence of unwillingness was 2%, and the higher rate of unwillingness was reported by Ehde et al. [5] . They conducted a cross-sectional study enrolling 486 patients with MS in an online survey. Two-thirds of the participants were willing to get the COVID-19 vaccine, while 15% were unwilling. In their study, higher age and noticing a higher risk of contracting COVID-19 were two independent factors of predicting willingness. In a survey by Huang et al. in the UK, 94% of patients with MS that were willing to get vaccines were higher than the general population (67%). Higher age, education level, and previous experience of influenza vaccine were associated with COVID-19 vaccination willingness. Female gender and no progressive type of the disease was associated with unwillingness in their survey [4] . Serrazina et al. reported willingness in 80% of 256 Portuguese patients with MS, while older patients and those with underlying diseases were more willing to obtain COVID-19 vaccines. Vaccination unwillingness was related to fewer concerns regarding COVID-19 infection and less impact of the disease on their lives [13] . In their study, the cases that wanted to postpone the vaccination were uncertain about the efficacy and safety of available vaccines. It is shown that if patients had enough vaccination information, they were more willing to get the COVID-19 vaccination, and more hesitancy was related to more desire to get information. It was reported that if patients got their information from health care providers or National MS Societies, they trust more [5] . Previously, a physician's advice was the most promoting factor of vaccination among the general population [15] . Vaccination of the MS population may prevent severe infection, hospitalization, disease exacerbation, and medication cessation, especially disease modifying therapies (DMTs) which are crucial for MS relief [16, 17] . So, providing enough trusty information by health care providers play an essential role in vaccination willingness among MS patients and preventing complications following no vaccination. Changing attitude in hesitant and unwilling individuals to get COVID-19 vaccines has been important to have a successful vaccination. According to the Wang et al. study, which is performed among 1047 and 1000 individuals, respectively, in the first wave in February and the third wave on August-September Fig. 2 The pooled prevalence of willingness to vaccination among patients with MS Fig. 3 The pooled prevalence of unwillingness to vaccination among patients with MS 2020 in Hong Kong, participants who worked and received the inf luenza vaccine in the last year accepted more to get the vaccine in the first wave. Hesitancy was raised in the second wave. The reasons for hesitation were vaccine efficacy (63.2%), the vaccine is not unnecessary (24.5%), the short time to manufacture vaccines (4.8%), and concern about safety or side effects of the vaccines (4.6%) [18] . In another cross-sectional study conducted in China in March and November-December among 791 individuals, there was a 3% decrease in willingness to get vaccines due to concern about approval. Changing in Fig. 4 The pooled prevalence of hesitancy to vaccination among patients with MS Fig. 5 All results of willingness, hesitancy, and unwillingness based on countries. Created with BioRender.com Clinical features of patients infected with 2019 novel coronavirus in Wuhan Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis Willingness to receive a COVID-19 vaccine in people with multiple sclerosis-UK MS Register survey Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States A global survey of potential acceptance of a COVID-19 vaccine Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis COVID-19 vaccination willingness among people with multiple sclerosis COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: a follow up survey during the initial vaccine rollout in 2021 COVID-19 vaccine hesitancy in multiple sclerosis: a cross-sectional survey 2021) Opinions, beliefs and knowledge of people with multiple sclerosis on COVID-19 pandemic and vaccine Vaccine hesitancy among people with multiple sclerosis Willingness to be vaccinated against COVID-19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients Attitudes toward vaccination in patients with multiple sclerosis: a report from Iran Vaccine hesitancy: a generation at risk Protecting people with multiple sclerosis through vaccination Vaccinations in patients with multiple sclerosis: a Delphi consensus statement Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong, China: repeated crosssectional surveys Changes in attitudes towards the COVID-19 vaccine and the willingness to get vaccinated among adults in Poland: analysis of serial, cross-sectional, representative surveys